Medetomidine is a veterinary sedative that now appears in much of the illegal fentanyl sold in the Mid-Atlantic, often without the buyer knowing it is there. It deepens sedation during an overdose, it does not respond to naloxone, and stopping it can trigger a withdrawal syndrome that has sent many patients to intensive care.

If you use fentanyl, or love someone who does, medetomidine changes what an overdose looks like and what quitting involves. Recognizing the risks makes it easier to decide when to get help, and to choose medically supervised care over trying to stop alone.

What Is Medetomidine?

Medetomidine is an alpha-2 adrenergic agonist sedative approved to sedate and relieve pain in dogs. It is not approved for human use, and the Centers for Disease Control and Prevention (CDC) describes it as more potent and longer-acting than both xylazine and clonidine.

Alpha-2 agonists slow the nervous system by lowering heart rate, blood pressure, and alertness. A closely related drug, dexmedetomidine, is approved for sedating patients in hospitals, where doctors can monitor breathing and heart rhythm. On the street, there is no monitoring, and the dose in any bag of fentanyl is unknown.

Medetomidine is not an opioid. That difference shapes almost every risk below, because the medications built to reverse an opioid overdose do not act on it.

What is the Medetomidine Street Name?

Medetomidine has no widely recognized street name, because most people never set out to buy it. It typically arrives mixed into fentanyl, so someone can use it for weeks without knowing it is there.

Some news reports call the combination of fentanyl and medetomidine “rhino tranq.” Because no single medetomidine street name is in common use, the safest assumption in the Mid-Atlantic is that any fentanyl may contain it. Lab testing and drug-checking programs are the only reliable ways to confirm what a sample holds.

Why Medetomidine Is Replacing Xylazine

Medetomidine is spreading through the same fentanyl supply that once carried xylazine, and Philadelphia shows the shift most clearly. In the last four months of 2024, medetomidine turned up in 72% of opioid samples tested in the city, while xylazine detection fell from 98% to 31%.

The trend reaches well beyond one city. CDC data show national lab reports of medetomidine climbing from 247 in 2023 to 8,233 in 2025, with more than half coming from the Northeast.

Maryland has seen it too. Medetomidine has been in the state’s illicit drug supply since July 2022, with most samples from Cecil County, near Philadelphia, and a growing presence in Baltimore City and in Harford, St. Mary’s, and Wicomico counties. Harford County is home to Ashley’s main campus and its Bel Air outpatient location.

The rise of xylazine (tranq) follows a familiar pattern, though the two drugs differ. Baltimore health officials note that medetomidine has not been linked to the severe wounds xylazine causes. Its danger shows up in the heart, blood pressure, and level of consciousness.

Medetomidine Overdose Can Outlast Naloxone

A medetomidine overdose combines the breathing risk of fentanyl with a sedative that slows the heart and keeps a person unconscious for longer. Since fentanyl is involved in most of these overdoses, the danger is layered: an opioid that stops breathing and a sedative that suppresses the heart.

Signs of a medetomidine overdose can include:

  • Deep sedation or unresponsiveness that lasts longer than expected
  • A very slow heart rate, reported as low as 32 beats per minute
  • Low blood pressure
  • Slow, shallow, or stopped breathing
  • Continued sleepiness even after breathing returns

Naloxone (Narcan) still matters. It reverses fentanyl and can restore breathing, so give naloxone whenever you suspect an opioid overdose. It will not wake someone from medetomidine sedation, though, so a person may keep breathing but remain unresponsive. Call 911, stay with them, and keep checking their breathing until help arrives.

This is part of why fentanyl is so dangerous right now. The supply changes faster than most people can track, and each new additive brings risks naloxone alone cannot address.

What Does Medetomidine Withdrawal Look Like?

Medetomidine withdrawal often looks like an extreme version of clonidine withdrawal, with a racing heart and dangerously high blood pressure. It differs from fentanyl withdrawal and can be life-threatening without medical care.

The CDC reports that symptoms may begin within hours of last use and peak 18 to 36 hours later. Among 165 Philadelphia patients hospitalized with suspected medetomidine withdrawal, 91% were admitted to intensive care, and nearly one in four needed a breathing tube. Standard opioid withdrawal medications often did not control their symptoms.

Withdrawal symptomWhat it can look like
Rapid heart rate (tachycardia)Heart rate over 100 beats per minute; median peak of 145 among Philadelphia patients
Severe high blood pressureReadings as high as 195/122 or more, raising risk of heart and brain injury
Vomiting and nauseaIntense, ongoing vomiting that makes it hard to keep down fluids or oral medications
Agitation and anxietyRestlessness, fear, and difficulty staying calm
TremorShaking hands or body
Changing alertnessSwinging between drowsiness and agitation
Chest painPressure or pain that can signal strain on the heart

Because fentanyl is almost always present too, people often experience opioid withdrawal at the same time. The combination is why medetomidine withdrawal is not something to wait out at home.

How Medetomidine Treatment Begins

Medetomidine treatment starts with medical stabilization, because the withdrawal symptoms that put people in intensive care need round-the-clock monitoring. Clinicians typically treat opioid withdrawal alongside the medetomidine symptoms, and may use alpha-2 agonist medications such as clonidine or dexmedetomidine to calm the heart and blood pressure.

Severe symptoms such as chest pain, very high blood pressure, confusion, or vomiting that won’t stop call for a hospital emergency department first. Once someone is medically stable, medically supervised detox and ongoing care help them stay safe. Fentanyl detox is so hard because of how quickly the drug reshapes the brain, and adding a sedative like medetomidine makes stopping alone even riskier.

Detox is the beginning, not the whole plan. Ashley’s opioid addiction treatment combines medical care, medication-assisted treatment, and therapy. Care continues through inpatient care on the Havre de Grace campus and outpatient programs in Bel Air, so recovery keeps moving after the body stabilizes.

If you or someone you love uses fentanyl in Maryland, medetomidine may already be part of what you’re facing, and you don’t have to manage it alone. Call 800-799-4673 or reach out to our Admissions team to talk through safe next steps. If someone is unresponsive or struggling to breathe, call 911 now. If you’re in crisis or thinking about harming yourself, call or text 988 to reach the Suicide & Crisis Lifeline.